Troy Tazbaz

1 month ago | jamanetwork.com | Leo Anthony Celi |Haider Warraich |Troy Tazbaz |Robert M. Califf

[Skip to Navigation] PDF Full Text Share X Facebook Email LinkedIn Cite Permissions Comment & Response AI in Medicine JAMA. 2025;333(11):1003.

2 months ago | jamanetwork.com | Troy Tazbaz |Robert M. Califf |Haider Warraich

In Reply The US Food and Drug Administration (FDA) is committed to including patient perspectives in the development and evaluation of all medical products, and AI- and machine learning (ML)–enabled products are no different.

Oct 15, 2024 | jamanetwork.com | Haider Warraich |Troy Tazbaz |Robert M. Califf

Abstract Importance  Advances in artificial intelligence (AI) must be matched by efforts to better understand and evaluate how AI performs across health care and biomedicine as well as develop appropriate regulatory frameworks.